Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THY121
MIFTS: 67

Thyroid Gland Anaplastic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thyroid Gland Anaplastic Carcinoma

About this section

MalaCards integrated aliases for Thyroid Gland Anaplastic Carcinoma:

Name: Thyroid Gland Anaplastic Carcinoma 12 15
Anaplastic Thyroid Carcinoma 12 20 58
Thyroid Cancer, Anaplastic 20 6
Anaplastic Thyroid Cancer 74 20
Thyroid Carcinoma, Anaplastic 20
Thyroid Carcinoma Anaplastic 54

Characteristics:

Orphanet epidemiological data:

58
anaplastic thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:0080522
NCIt 50 C3878
MESH via Orphanet 45 C536910
ICD10 via Orphanet 33 C73
UMLS via Orphanet 72 C0238461
Orphanet 58 ORPHA142
Sources

Summaries for Thyroid Gland Anaplastic Carcinoma

About this section
GARD : 20 Anaplastic thyroid cancer (ATC) accounts for less than 2% of all thyroid cancers and is the most aggressive type of thyroid cancer. Most cases of anaplastic thyroid cancer are diagnosed in the sixth to seventh decade of life. Women are more likely to be affected than men. ATC generally occurs in individuals with a history of goiter or thyroid cancer. A history of head and neck radiation or exposure to radioactive materials may also increase the risk for ATC. Patients with ATC generally present with a rapidly-growing neck mass which may cause trouble swallowing (dysphagia), coughing, neck pain, and trouble breathing (dyspnea). Metastasis is present in more than half of individuals at the time of diagnosis. Patients with metastases may also present with bone pain, lymph node enlargement, weakness, and neurological deficits. Treatment of ATC is mostly palliative.

MalaCards based summary : Thyroid Gland Anaplastic Carcinoma, also known as anaplastic thyroid carcinoma, is related to thyroid carcinoma and differentiated thyroid carcinoma. An important gene associated with Thyroid Gland Anaplastic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Development HGF signaling pathway. The drugs Pemetrexed and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and skeletal muscle, and related phenotypes are anaplastic thyroid carcinoma and broad neck

Disease Ontology : 12 A thyroid gland carcinoma that is composed of undifferentiated cells.

Wikipedia : 74 Anaplastic thyroid cancer (ATC), also known as anaplastic thyroid carcinoma, is an aggressive form of... more...

Sources

Related Diseases for Thyroid Gland Anaplastic Carcinoma

About this section

Diseases related to Thyroid Gland Anaplastic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 384)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma 32.5 TSHR TPO TG RET PTEN PIK3CA
2 differentiated thyroid carcinoma 31.8 TSHR TPO TP53 TG RET PAX8
3 thyroid tumor 31.7 RET BRAF
4 papillary carcinoma 31.5 TSHR TPO TG RET PAX8 NKX2-1
5 thyroiditis 31.5 TSHR TPO TG RET CALCA
6 graves disease 1 31.3 TSHR TPO TG CALCA
7 multinodular goiter 31.3 TSHR TPO TG PAX8 NKX2-1 CALCA
8 endemic goiter 31.1 TSHR TPO TG
9 adenoma 31.1 TSHR TP53 TG RET PIK3CA CDH1
10 hyperthyroidism 31.1 TSHR TPO TG CALCA
11 graves' disease 31.0 TSHR TPO TG PAX8
12 nodular goiter 31.0 TSHR TPO TG RET CALCA BRAF
13 hypothyroidism 31.0 TSHR TPO TG RET PAX8 NKX2-1
14 thyroid gland medullary carcinoma 30.9 TG RET PAX8 NKX2-1 CALCA
15 substernal goiter 30.9 TG CALCA
16 thyroid carcinoma, familial medullary 30.9 TG RET NKX2-1 CALCA BRAF
17 melanoma 30.9 TP53 PTEN PIK3CA MIR34C MIR19A MIR17
18 thyroid cancer, nonmedullary, 2 30.9 TSHR TG PTEN PAX8 CALCA BRAF
19 thyroid gland follicular carcinoma 30.9 TSHR TPO TP53 TG RET PTEN
20 hypoparathyroidism 30.8 TPO RET CALCA
21 lung cancer susceptibility 3 30.8 TP53 PIK3CA NKX2-1 MIR30A MIR17 CDKN1A
22 goiter 30.8 TSHR TPO TG RET PAX8 NKX2-1
23 acute thyroiditis 30.8 TPO TG CALCA
24 papillary adenocarcinoma 30.8 TP53 NKX2-1 MIR30A CDH1
25 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 TSHR TPO TG
26 subacute thyroiditis 30.7 TSHR TPO TG
27 exophthalmos 30.7 TSHR TPO TG
28 endometrial cancer 30.7 TP53 RET PTEN PIK3CA PAX8 NKX2-1
29 mucoepidermoid carcinoma 30.7 TP53 TG NKX2-1 CDH1 CALCA
30 papillary thyroid microcarcinoma 30.7 TSHR TG NKX2-1 CALCA BRAF
31 cowden syndrome 30.7 TP53 RET PTEN PIK3CA MIR19A
32 oral squamous cell carcinoma 30.7 TP53 MIR34C MIR30D MIR19A MIR17 CDH1
33 follicular adenoma 30.7 TSHR TPO TG RET PTEN PAX8
34 leukemia, chronic myeloid 30.7 TP53 MIR19A MIR18A MIR17 CDKN1A BRAF
35 lynch syndrome 30.7 TP53 PTEN PIK3CA MIR17 BRAF
36 neuroblastoma 30.7 TP53 RET PTEN PIK3CA MIR17 CDKN1A
37 squamous cell carcinoma 30.6 TP53 PTEN PIK3CA CDKN1A CDH1 BRAF
38 gastrointestinal stromal tumor 30.6 TP53 PTEN CDKN1A CDH1 BRAF
39 leukemia, chronic lymphocytic 30.6 TP53 PTEN MIR30D MIR30A MIR19A MIR17
40 kidney cancer 30.6 TP53 PTEN PIK3CA MIR17
41 squamous cell carcinoma, head and neck 30.6 TP53 PTEN PIK3CA MIR19A MIR18A CDKN1A
42 thyroid gland disease 30.6 TSHR TPO TG RET PAX8 NKX2-1
43 thyroid gland cancer 30.6 TSHR TPO TP53 TG RET PTEN
44 adenocarcinoma 30.6 TP53 RET PTEN PIK3CA NKX2-1 CDKN1A
45 medulloblastoma 30.5 TP53 PTEN PIK3CA MIR30D MIR19A MIR18A
46 malignant pleural mesothelioma 30.5 TP53 NKX2-1 MIR17
47 ovarian cancer 30.4 TP53 PTEN PIK3CA PAX8 MIR34C MIR30A
48 thyroid cancer, nonmedullary, 1 10.7
49 mechanical strabismus 10.6 TPO TG
50 thyroid gland mucoepidermoid carcinoma 10.6 TG CALCA

Graphical network of the top 20 diseases related to Thyroid Gland Anaplastic Carcinoma:



Diseases related to Thyroid Gland Anaplastic Carcinoma
Sources

Symptoms & Phenotypes for Thyroid Gland Anaplastic Carcinoma

About this section

Human phenotypes related to Thyroid Gland Anaplastic Carcinoma:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anaplastic thyroid carcinoma 58 31 obligate (100%) Obligate (100%) HP:0011779
2 broad neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0000475
3 hoarse voice 58 31 hallmark (90%) Very frequent (99-80%) HP:0001609
4 nodular goiter 58 31 hallmark (90%) Very frequent (99-80%) HP:0005994
5 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
6 vocal cord paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0001605
7 neoplasm of the lung 58 31 frequent (33%) Frequent (79-30%) HP:0100526
8 respiratory distress 58 31 frequent (33%) Frequent (79-30%) HP:0002098
9 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
10 upper airway obstruction 58 31 frequent (33%) Frequent (79-30%) HP:0002781
11 pain 58 31 frequent (33%) Frequent (79-30%) HP:0012531
12 laryngotracheal stenosis 58 31 frequent (33%) Frequent (79-30%) HP:0004894
13 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
14 hemoptysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002105
15 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
16 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
17 stridor 58 31 occasional (7.5%) Occasional (29-5%) HP:0010307
18 neoplasm of the skeletal system 58 31 occasional (7.5%) Occasional (29-5%) HP:0010622
19 abnormal skeletal muscle morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0011805
20 tracheoesophageal fistula 58 31 very rare (1%) Very rare (<4-1%) HP:0002575
21 malignant neoplasm of the central nervous system 58 31 very rare (1%) Very rare (<4-1%) HP:0100836
22 dyspnea 58 Occasional (29-5%)
23 goiter 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Thyroid Gland Anaplastic Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.15 BRAF CDH1 CDKN1A NKX2-1 PAX8 PIK3CA
2 digestive/alimentary MP:0005381 10.01 BRAF CDH1 CDKN1A NKX2-1 PTEN RET
3 limbs/digits/tail MP:0005371 9.97 BRAF CDKN1A PAX8 PTEN RET TG
4 neoplasm MP:0002006 9.91 BRAF CDH1 CDKN1A NKX2-1 PIK3CA PTEN
5 no phenotypic analysis MP:0003012 9.76 ADGRE5 CDH1 CDKN1A NKX2-1 PAX8 PIK3CA
6 reproductive system MP:0005389 9.7 BRAF CDH1 CDKN1A NKX2-1 PAX8 PIK3CA
7 skeleton MP:0005390 9.32 BRAF CDKN1A NKX2-1 PAX8 PIK3CA PTEN
Sources

Drugs & Therapeutics for Thyroid Gland Anaplastic Carcinoma

About this section

Drugs for Thyroid Gland Anaplastic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
2
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
3
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
4
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
5
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
6
Hydroxyurea Approved Phase 2 127-07-1 3657
7
Fluorouracil Approved Phase 2 51-21-8 3385
8
Sodium citrate Approved, Investigational Phase 2 68-04-2
9
Tamoxifen Approved Phase 2 10540-29-1 2733526
10
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
11
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
12
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
13
tannic acid Approved Phase 2 1401-55-4
14
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
15
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
16
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
17
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
18
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
19
Ipilimumab Approved Phase 2 477202-00-9
20
nivolumab Approved Phase 2 946414-94-4
21
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
22
Trametinib Approved Phase 2 871700-17-3 11707110
23
Pembrolizumab Approved Phase 2 1374853-91-4
24
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
25
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
26
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
27
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
28
Lenvatinib Approved, Investigational Phase 2 417716-92-8
29
Bevacizumab Approved, Investigational Phase 2 216974-75-3
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
32 Molgramostim Investigational Phase 2 99283-10-0
33
Efatutazone Investigational Phase 1, Phase 2 223132-37-4
34 Folic Acid Antagonists Phase 2
35 Vitamin B Complex Phase 2
36 Vitamin B9 Phase 2
37 Folate Phase 2
38 Cola Phase 2
39 Liver Extracts Phase 2
40 Vaccines Phase 2
41 Antimetabolites Phase 2
42 Citrate Phase 2
43 Hormone Antagonists Phase 2
44 Estrogens Phase 2
45 Estrogen Receptor Antagonists Phase 2
46 Estrogen Antagonists Phase 2
47 Antineoplastic Agents, Hormonal Phase 2
48 Estrogen Receptor Modulators Phase 2
49 Anti-HIV Agents Phase 2
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT] Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2) Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
3 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
4 Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Unknown status NCT03565536 Phase 2 Nexavar
5 Phase 2 Trial of Pemetrexed (Alimtaâ„¢) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
6 Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid Completed NCT00060242 Phase 2 fosbretabulin disodium
7 A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer Completed NCT00095836 Phase 2 Gefitinib
8 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
9 An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
10 A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer Completed NCT00004089 Phase 2 fluorouracil;hydroxyurea;paclitaxel
11 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
12 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE) Completed NCT02726503 Phase 2 Lenvatinib
13 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed NCT01240590 Phase 1, Phase 2 Crolibulin;Cisplatin
14 Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer Completed NCT03211117 Phase 2 Docetaxel;Doxorubicin Hydrochloride
15 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
16 A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer Completed NCT00625846 Phase 2 Pazopanib Hydrochloride
17 Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies Completed NCT02404441 Phase 1, Phase 2
18 A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
19 Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO) Recruiting NCT04739566 Phase 2 Dabrafenib;Trametinib
20 A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Recruiting NCT02244463 Phase 2 MLN0128
21 Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer Recruiting NCT02688608 Phase 2 Pembrolizumab
22 A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib Recruiting NCT04238624 Phase 2 Dabrafenib;Trametinib
23 Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer Recruiting NCT04731740 Phase 2 Lenvatinib;Chemotherapy
24 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Recruiting NCT04552769 Phase 2 Abemaciclib
25 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Autologous Tumor Infiltrating Lymphocytes LN-145-S1;Cyclophosphamide;Fludarabine
26 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Atezolizumab;Cobimetinib;Nab-paclitaxel;Paclitaxel;Vemurafenib
27 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
28 A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma Recruiting NCT04592484 Phase 1, Phase 2
29 A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer Active, not recruiting NCT01236547 Phase 2 Paclitaxel;Pazopanib Hydrochloride
30 A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer Active, not recruiting NCT02152137 Phase 2 efatutazone;paclitaxel
31 A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer Active, not recruiting NCT03246958 Phase 2 Nivolumab;Ipilimumab
32 Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer Not yet recruiting NCT04675710 Phase 2 Dabrafenib;Trametinib
33 A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer Not yet recruiting NCT04574817 Phase 2 HX008
34 Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Not yet recruiting NCT04171622 Phase 2 Lenvatinib
35 Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation] Terminated NCT00077103 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;fosbretabulin disodium
36 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Terminated NCT02657369 Phase 2 Lenvatinib 24 mg
37 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
38 Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid Terminated NCT00126568 Phase 2 sorafenib tosylate
39 A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer Terminated NCT00603941 Phase 1, Phase 2 CS-7017;Paclitaxel
40 Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Terminated NCT00804830 Phase 2 Bevacizumab
41 A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer Terminated NCT03002623 Phase 2 CUDC-907
42 Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer Terminated NCT00115739 Phase 2 Imatinib
43 Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Withdrawn NCT02289144 Phase 2 Ceritinib
44 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
45 B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
46 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
47 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
48 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
49 A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer Recruiting NCT04420754 Phase 1
50 A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer Recruiting NCT03975231 Phase 1 Dabrafenib;Trametinib

Search NIH Clinical Center for Thyroid Gland Anaplastic Carcinoma

Sources

Genetic Tests for Thyroid Gland Anaplastic Carcinoma

About this section
Sources

Anatomical Context for Thyroid Gland Anaplastic Carcinoma

About this section

MalaCards organs/tissues related to Thyroid Gland Anaplastic Carcinoma:

40
Thyroid, Lymph Node, Skeletal Muscle, Endothelial, Lung, Liver, Heart
Sources

Publications for Thyroid Gland Anaplastic Carcinoma

About this section

Articles related to Thyroid Gland Anaplastic Carcinoma:

(show top 50) (show all 1233)
# Title Authors PMID Year
1
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. 6
8423216 1993
2
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. 6
1565144 1992
3
Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. 47
20198305 2010
4
Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model. 61 54
19727716 2010
5
R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. 54 61
19230027 2009
6
Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. 54 61
18509005 2008
7
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. 47
18429962 2008
8
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. 61 54
18458053 2008
9
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. 54 61
18000091 2008
10
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. 47
17563749 2007
11
Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines. 61 54
17671725 2007
12
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. 61 54
17327374 2007
13
Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. 54 61
16899627 2006
14
Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. 54 61
16551737 2006
15
Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. 54 61
16647341 2006
16
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. 54 61
16331265 2006
17
BRAF is a therapeutic target in aggressive thyroid carcinoma. 54 61
16533790 2006
18
Differential effects of TGF-beta1 on telomerase activity in thyroid carcinoma cell lines. 54 61
16288728 2005
19
Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. 54 61
16264365 2005
20
Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. 61 54
16278386 2005
21
RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. 54 61
15980887 2005
22
Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. 61 54
16029487 2005
23
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. 61 54
15880523 2005
24
Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. 54 61
15650765 2005
25
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. 54 61
15195111 2004
26
[Genetic causes of the thyroid carcinomas]. 61 54
15584614 2004
27
Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. 54 61
14654945 2004
28
Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. 61 54
12915687 2003
29
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. 61 54
12843138 2003
30
Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. 61 54
12495476 2002
31
Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. 61 54
12432546 2002
32
Multistep carcinogenesis in anaplastic thyroid carcinoma: a case report. 61 54
11902457 2002
33
Apoptosis: life through planned cellular death regulating mechanisms, control systems, and relations with thyroid diseases. 61 54
11838727 2002
34
BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). 61 54
11453659 2001
35
Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. 61 54
10942601 2000
36
N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. 61 54
10521809 1999
37
Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells. 61 54
10459856 1999
38
Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. 54 61
10213482 1999
39
Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. 54 61
9768682 1998
40
p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. 61 54
9038381 1997
41
Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. 54 61
8892315 1996
42
Thyroid anaplastic carcinoma producing granulocyte-colony-stimulating factor and parathyroid hormone-related protein. 61 54
7549149 1995
43
Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas. 54 61
8612724 1995
44
Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid. 61 54
8050090 1994
45
p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. 61 54
1483945 1992
46
The molecular biology of the human anaplastic thyroid carcinoma cell. 61 54
1726928 1991
47
Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. 54 61
1712540 1991
48
HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1. 61
33359451 2021
49
A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. 61
33572167 2021
50
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic. 61
33587835 2021
Sources

Variations for Thyroid Gland Anaplastic Carcinoma

About this section

ClinVar genetic disease variations for Thyroid Gland Anaplastic Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802

Cosmic variations for Thyroid Gland Anaplastic Carcinoma:

9 (show top 50) (show all 5257)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90416635 ZNF703 thyroid,NS,carcinoma,anaplastic carcinoma c.1232C>T p.A411V 8:37698133-37698133 27
2 COSM84513642 ZNF276 thyroid,NS,carcinoma,anaplastic carcinoma c.*2596A>T p.? 16:89740842-89740842 27
3 COSM101980343 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 27
4 COSM104240109 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 27
5 COSM104886876 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 27
6 COSM90659403 VHL thyroid,NS,carcinoma,anaplastic carcinoma c.289C>T p.P97S 3:10142136-10142136 27
7 COSM88298168 VHL thyroid,NS,carcinoma,anaplastic carcinoma c.289C>T p.P97S 3:10142136-10142136 27
8 COSM102449047 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.28G>C p.E10Q 21:43095696-43095696 27
9 COSM99372056 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.247G>C p.E83Q 21:43095696-43095696 27
10 COSM112017925 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.78G>A p.M26I 21:43095489-43095489 27
11 COSM99368161 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.297G>A p.M99I 21:43095489-43095489 27
12 COSM112020403 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.28G>C p.E10Q 21:43095696-43095696 27
13 COSM85196814 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.247G>C p.E83Q 21:43095696-43095696 27
14 COSM85193419 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.297G>A p.M99I 21:43095489-43095489 27
15 COSM102445292 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.78G>A p.M26I 21:43095489-43095489 27
16 COSM86824282 TYRO3 thyroid,NS,carcinoma,anaplastic carcinoma c.2194C>T p.P732S 15:41573727-41573727 27
17 COSM135709676 TYRO3 thyroid,NS,carcinoma,anaplastic carcinoma c.2059C>T p.P687S 15:41573727-41573727 27
18 COSM131092631 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1672G>A p.V558M 14:81143730-81143730 27
19 COSM85466293 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1703T>C p.I568T 14:81143761-81143761 27
20 COSM85466972 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1789G>C p.V597L 14:81143847-81143847 27
21 COSM85466282 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1514G>A p.S505N 14:81143572-81143572 27
22 COSM131089965 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1911G>T p.M637I 14:81143969-81143969 27
23 COSM85472824 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1911G>T p.M637I 14:81143969-81143969 27
24 COSM85469801 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.842G>C p.S281T 14:81139828-81139828 27
25 COSM131087195 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.842G>C p.S281T 14:81139828-81139828 27
26 COSM85475366 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1672G>A p.V558M 14:81143730-81143730 27
27 COSM131089960 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1898A>C p.D633A 14:81143956-81143956 27
28 COSM131083598 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1703T>C p.I568T 14:81143761-81143761 27
29 COSM131084149 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1789G>C p.V597L 14:81143847-81143847 27
30 COSM85472813 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1898A>C p.D633A 14:81143956-81143956 27
31 COSM131083592 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1514G>A p.S505N 14:81143572-81143572 27
32 COSM101185486 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1292A>G p.Y431C 16:2063049-2063049 27
33 COSM151512883 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.5038G>A p.D1680N 16:2088092-2088092 27
34 COSM150313015 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4912G>A p.D1638N 16:2088092-2088092 27
35 COSM147690582 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4984G>A p.D1662N 16:2088092-2088092 27
36 COSM151380590 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.793G>T p.G265C 16:2057123-2057123 27
37 COSM110102153 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4804G>A p.D1602N 16:2088092-2088092 27
38 COSM147690543 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 27
39 COSM149800713 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 27
40 COSM151746971 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 27
41 COSM110124471 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.682G>T p.G228C 16:2057123-2057123 27
42 COSM149823983 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.793G>T p.G265C 16:2057123-2057123 27
43 COSM150574934 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4906G>A p.D1636N 16:2088092-2088092 27
44 COSM90402476 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.5044G>A p.D1682N 16:2088092-2088092 27
45 COSM151370140 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 27
46 COSM87033564 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1439A>G p.Y480C 16:2063049-2063049 27
47 COSM87027114 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 27
48 COSM149807155 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1439A>G p.Y480C 16:2063049-2063049 27
49 COSM101199474 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.646G>T p.G216C 16:2057123-2057123 27
50 COSM148998555 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.793G>T p.G265C 16:2057123-2057123 27

Copy number variations for Thyroid Gland Anaplastic Carcinoma from CNVD:

7 (show all 18)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 18562 1 146514610 148102224 Gain Anaplastic thyroid cancer
2 57418 11 63321142 66212707 Gain CCND1 Anaplastic thyroid cancer
3 68082 12 47384342 48639263 Gain Anaplastic thyroid cancer
4 78984 13 61113549 63481793 Loss Anaplastic thyroid cancer
5 99673 16 28082639 28922556 Gain Anaplastic thyroid cancer
6 114238 17 45949240 46466966 Gain Anaplastic thyroid cancer
7 124653 19 11950033 12150103 Gain Anaplastic thyroid cancer
8 128382 19 40542097 41211643 Gain Anaplastic thyroid cancer
9 152529 20 31497814 33184582 Gain Anaplastic thyroid cancer
10 153944 20 41887694 44153298 Gain UBE2C Anaplastic thyroid cancer
11 161614 22 19538297 19939137 Gain Anaplastic thyroid cancer
12 164302 22 36003989 36444264 Gain Anaplastic thyroid cancer
13 171639 3 170900000 182700000 Copy number PIK3CA Anaplastic thyroid cancer
14 182004 4 132076562 133123563 Loss Anaplastic thyroid cancer
15 188265 4 61317501 66095641 Loss Anaplastic thyroid cancer
16 211600 6 33165527 33494594 Gain Anaplastic thyroid cancer
17 225370 7 45400000 54000000 Amplification EGFR Anaplastic thyroid cancer
18 227803 7 72035816 72259198 Gain Anaplastic thyroid cancer
Sources

Expression for Thyroid Gland Anaplastic Carcinoma

About this section
Search GEO for disease gene expression data for Thyroid Gland Anaplastic Carcinoma.
Sources

Pathways for Thyroid Gland Anaplastic Carcinoma

About this section

Pathways related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 36
Show member pathways
 12.81 TSHR TPO TG PAX8 CDKN1A BRAF
2
Development HGF signaling pathway 23
Show member pathways
 12.66 TP53 PTEN PIK3CA CDH1 BRAF
3
Gastric cancer 36
Show member pathways
 12.65 TP53 PTEN PIK3CA CDKN1A CDH1 BRAF
4
ErbB signaling pathway 36 1
Show member pathways
 12.56 TP53 PTEN PIK3CA CDKN1A BRAF
5
Endometrial cancer 36
Show member pathways
 12.5 TP53 RET PTEN PIK3CA PAX8 CDKN1A
6
Glioma 36
Show member pathways
 12.47 TP53 RET PTEN PIK3CA CDKN1A CDH1
7
Development IGF-1 receptor signaling 23
Show member pathways
 12.34 TP53 PTEN PIK3CA CDKN1A
8
Human T-cell leukemia virus 1 infection 36
12.29 TP53 PTEN PIK3CA CDKN1A
9
Pathways in cancer 36
12.28 TP53 RET PTEN PIK3CA PAX8 CDKN1A
10
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.26 TP53 PTEN PIK3CA CDKN1A
11
Proteoglycans in cancer 36
12.25 TP53 PIK3CA CDKN1A BRAF
12
DNA Damage Response 1
Show member pathways
 12.25 TP53 PTEN MIR19A MIR18A MIR17 CDKN1A
13
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.16 TP53 PTEN PIK3CA CDKN1A BRAF
14
Colorectal Cancer Metastasis 63
12.13 TP53 CDKN1A CDH1 BRAF
15
Cellular senescence (KEGG) 36
12.09 TP53 PTEN PIK3CA CDKN1A
16
Integrated Breast Cancer Pathway 1
12.07 TP53 PTEN CDH1 BRAF
17
FoxO signaling pathway 36
Show member pathways
 12 PTEN PIK3CA CDKN1A BRAF
18
DNA Damage Response (only ATM dependent) 1
11.91 TP53 PTEN PIK3CA CDKN1A
19
Glioblastoma Multiforme 63
11.88 TP53 PTEN CDKN1A BRAF
20
Senescence and Autophagy in Cancer 1
11.85 TP53 PTEN CDKN1A BRAF
21
MicroRNAs in cancer 36
11.81 TP53 PTEN PIK3CA MIR34C MIR30D MIR30A
22
VEGF Pathway (Tocris) 60
Show member pathways
 11.76 RET PIK3CA BRAF
23
Small cell lung cancer 36
11.76 TP53 PTEN PIK3CA CDKN1A
24
Platinum drug resistance 36
11.69 TP53 PIK3CA CDKN1A
25
Pathways Affected in Adenoid Cystic Carcinoma 1
11.64 TP53 PTEN PIK3CA
26
Bladder cancer 36 1
11.64 TP53 CDKN1A CDH1 BRAF
27
Central carbon metabolism in cancer 36
11.6 TP53 RET PTEN PIK3CA
28
Parkinsons Disease Pathway 1
11.58 MIR34C MIR30A MIR19A MIR18A MIR17
29
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.57 TSHR PIK3CA PAX8 BRAF
30
Copper homeostasis 1
11.53 TP53 PTEN PIK3CA
31
miRNAs involved in DNA damage response 1
11.49 TP53 MIR34C CDKN1A
32
Integrated Cancer Pathway 1
11.44 TP53 PTEN CDKN1A
33
LncRNA-mediated mechanisms of therapeutic resistance 1
10.74 TP53 CDKN1A
34
Transcriptional activation of p53 responsive genes 65
Show member pathways
 10.55 TP53 CDKN1A
35
Thyroxine (Thyroid Hormone) Production 1
10.32 TSHR TPO TG
Sources

GO Terms for Thyroid Gland Anaplastic Carcinoma

About this section

Cellular components related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TPO TG MIR30D MIR30A MIR19A MIR18A
2 extracellular vesicle GO:1903561 9.26 MIR30D MIR30A MIR19A MIR17

Biological processes related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 TP53 PTEN MIR19A CDKN1A BRAF
2 positive regulation of gene expression GO:0010628 9.91 TP53 RET PTEN NKX2-1 BRAF
3 gene silencing by miRNA GO:0035195 9.88 MIR34C MIR30D MIR30A MIR19A MIR18A MIR17
4 response to drug GO:0042493 9.77 TP53 RET PTEN CDKN1A CDH1
5 response to organic substance GO:0010033 9.73 PTEN CDKN1A CDH1
6 cellular response to nerve growth factor stimulus GO:1990090 9.61 PTEN CALCA BRAF
7 response to arsenic-containing substance GO:0046685 9.55 PTEN CDKN1A
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR34C MIR17
9 hormone biosynthetic process GO:0042446 9.52 TPO TG
10 endothelial cell migration GO:0043542 9.5 PTEN PIK3CA CALCA
11 positive regulation of B cell receptor signaling pathway GO:0050861 9.49 MIR19A MIR18A
12 regulation of axon regeneration GO:0048679 9.48 PTEN BRAF
13 signal transduction by p53 class mediator GO:0072331 9.46 TP53 CDKN1A
14 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.33 TP53 PTEN MIR17
15 thyroid-stimulating hormone signaling pathway GO:0038194 9.26 TSHR PAX8
16 negative regulation of sprouting angiogenesis GO:1903671 9.26 MIR34C MIR19A MIR18A MIR17
17 thyroid gland development GO:0030878 8.92 TG PAX8 NKX2-1 BRAF

Molecular functions related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8
Sources

Sources for Thyroid Gland Anaplastic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....